Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
FDA Approves New CRISPR Gene-Editing Treatment
05:59pm, Tuesday, 16'th Jan 2024
The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
03:19pm, Tuesday, 16'th Jan 2024
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 1
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
08:15am, Tuesday, 16'th Jan 2024
Investors who are willing to accept risk can be compensated with more upside potential. CRISPR is in the early stages of rolling out gene therapy products that could be very valuable.
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
04:56pm, Monday, 15'th Jan 2024
CRISPR passed several major miletones in its quest to bring its first treatment to market. The company has no product revenue, so it's prone to market-driven volatility.
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
01:30pm, Sunday, 14'th Jan 2024
CRISPR Therapeutics recently obtained approval for its gene therapy Casgevy. The therapy could generate close to $4 billion in annual revenue at its peak.
7 Healthcare Stocks Taking Medicine to the Next Level
12:54pm, Sunday, 14'th Jan 2024
While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to b
3 Cathie Wood Stocks to Start Off Your New Year Right
06:00am, Wednesday, 10'th Jan 2024
Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.
CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
11:25pm, Tuesday, 09'th Jan 2024
CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
2 low-priced gene therapy stocks to speculate on
08:26am, Monday, 08'th Jan 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
05:00am, Thursday, 04'th Jan 2024
CRISPR Therapeutics recently won regulatory approval for its first product. Casgevy, for blood disorders, has the potential to reach blockbuster status.
CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet
02:10am, Thursday, 04'th Jan 2024
CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure f
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
12:17pm, Wednesday, 03'rd Jan 2024
Betting on healthcare's future via healthcare stocks is one of the safest long-term bets you can make. Though changes and advances happen rapidly, healthcare is one industry that is here to stay.
2 gene-editing stocks reshaping hereditary disease treatments
07:16am, Tuesday, 02'nd Jan 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle
3 No-Brainer Growth Stocks to Buy for Less Than $100
09:05am, Monday, 01'st Jan 2024
PayPal remains a top fintech company in a massive industry that keeps growing. Palantir's business has turned a corner and is now profitable.
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
10:30am, Sunday, 31'st Dec 2023
Cathie Wood has purchased a large stake in CRISPR Therapeutics for her ARK Invest ETFs. The company won a landmark regulatory approval this year, but analysts think the therapy may get off to a slow s
